imatinib mesylate has been researched along with Viral Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
| Matter, M; Mumprecht, S; Ochsenbein, AF; Pavelic, V | 1 |
2 other study(ies) available for imatinib mesylate and Viral Diseases
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.
Topics: Animals; Autoimmune Diseases; Benzamides; Cell Proliferation; Diabetes Mellitus, Experimental; Imatinib Mesylate; Immunity; Immunologic Memory; Lymphocytic choriomeningitis virus; Mice; Piperazines; Pyrimidines; T-Lymphocytes, Cytotoxic; Virus Diseases | 2006 |